NASDAQ:MRTX Mirati Therapeutics (MRTX) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$58.70▼$58.7050-Day Range$58.70▼$59.2852-Week Range$27.30▼$64.41VolumeN/AAverage Volume2.76 million shsMarket Capitalization$4.12 billionP/E RatioN/ADividend YieldN/APrice Target$60.27 Stock AnalysisStock Analysis Get Mirati Therapeutics alerts: Email Address Mirati Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.08 Rating ScoreUpside/Downside2.7% Upside$60.27 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.68Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($11.39) to ($9.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.28 out of 5 starsMedical Sector916th out of 936 stocksPharmaceutical Preparations Industry428th out of 436 stocks 1.0 Analyst's Opinion Consensus RatingMirati Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.08, and is based on 1 buy rating, 11 hold ratings, and no sell ratings.Amount of Analyst CoverageMirati Therapeutics has received no research coverage in the past 90 days.Read more about Mirati Therapeutics' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for MRTX. Previous Next 0.0 Dividend Strength Dividend YieldMirati Therapeutics does not currently pay a dividend.Dividend GrowthMirati Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMirati Therapeutics has received a 74.62% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Clinical research services for cancer", "Basic medical research services", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Mirati Therapeutics is -0.68. Previous Next N/A News and Social Media Coverage Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mirati Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.26% of the stock of Mirati Therapeutics is held by insiders.Read more about Mirati Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Mirati Therapeutics are expected to grow in the coming year, from ($11.39) to ($9.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mirati Therapeutics is -4.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mirati Therapeutics is -4.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMirati Therapeutics has a P/B Ratio of 3.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Mirati Therapeutics Stock (NASDAQ:MRTX)Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.Read More Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here MRTX Stock News HeadlinesJanuary 10, 2024 | markets.businessinsider.comMirati Therapeutics Receives Marketing Authorization For KRAZATI From European CommissionJanuary 10, 2024 | finance.yahoo.comEuropean Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C MutationJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.December 25, 2023 | seekingalpha.comEvaluating Mirati Therapeutics' CVR Value In The Wake Of The Bristol Myers AcquisitionDecember 22, 2023 | reuters.comBristol Myers to buy schizophrenia drugmaker Karuna Therapeutics for $14 blnDecember 22, 2023 | msn.comKaruna Therapeutics soars after $14 billion takeover by Bristol MyersDecember 20, 2023 | msn.comCitigroup Downgrades Mirati Therapeutics (MRTX)December 20, 2023 | finance.yahoo.comMirati Therapeutics Inc EVP & Chief Scientific Officer Jamie Christensen Sells 2,387 SharesJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.December 15, 2023 | finance.yahoo.comInsider Sell Alert: EVP Benjamin Hickey Sells Shares of Mirati Therapeutics Inc (MRTX)December 12, 2023 | morningstar.comMirati Therapeutics Inc MRTXDecember 12, 2023 | finance.yahoo.comBillionaire Joe Lewis Keeps Trading Stocks Behind US Insider-Trading ChargesDecember 3, 2023 | benzinga.comMirati Therapeutics Stock (NASDAQ:MRTX), Short Interest ReportDecember 3, 2023 | benzinga.comMirati Therapeutics Stock (NASDAQ:MRTX) Dividends: History, Yield and DatesNovember 15, 2023 | benzinga.comMoore Kuehn Encourages PCTI, MRTX, CSTR, and BBAI Investors to Contact Law FirmNovember 10, 2023 | marketwatch.comMirati Therapeutics Gets CHMP Backing for KrazatiNovember 10, 2023 | reuters.comMirati's lung cancer drug gets EU's regulatory backingNovember 10, 2023 | finance.yahoo.comUPDATE 1-Mirati's lung cancer drug gets EU's regulatory backingSee More Headlines Receive MRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2023Today7/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MRTX CUSIPN/A CIK1576263 Webwww.mirati.com Phone(858) 332-3410FaxN/AEmployees587Year Founded2013Price Target and Rating Average Stock Price Target$60.27 High Stock Price Target$82.00 Low Stock Price Target$37.00 Potential Upside/Downside+2.7%Consensus RatingHold Rating Score (0-4)2.08 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($12.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-740,870,000.00 Net Margins-1,900.65% Pretax Margin-1,899.99% Return on Equity-82.15% Return on Assets-67.82% Debt Debt-to-Equity RatioN/A Current Ratio7.54 Quick Ratio7.40 Sales & Book Value Annual Sales$12.44 million Price / Sales331.01 Cash FlowN/A Price / Cash FlowN/A Book Value$17.31 per share Price / Book3.39Miscellaneous Outstanding Shares70,150,000Free Float67,861,000Market Cap$4.12 billion OptionableOptionable Beta0.77 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Charles M. Baum M.D. (Age 66)Ph.D., Founder, President, CEO & Director Comp: $1.07MDr. James G. Christensen Ph.D. (Age 56)Executive VP & Chief Scientific Officer Comp: $1.76MDr. Alan Bart Sandler M.D. (Age 67)Executive VP & Chief Medical Officer Comp: $591kMr. Aaron Ondrey (Age 48)Chief Financial Officer Ms. Betsy Gelfand CPAChief Accounting Officer, Principal Accounting Officer & VP of FinanceMr. John B. Moriarty Jr. (Age 56)J.D., Chief Legal Officer & Corporate Secretary Mr. Peter LeeChief Compliance OfficerMr. Michael E. Paolucci (Age 64)Chief People Officer Mr. Benjamin J. Hickey M.B.A. (Age 49)Chief Commercial Officer Comp: $769.03kDr. Kelly Covello Ph.D.VP & Head of Medical AffairsMore ExecutivesKey CompetitorsACADIA PharmaceuticalsNASDAQ:ACADSyndax PharmaceuticalsNASDAQ:SNDXExelixisNASDAQ:EXELMyoKardiaNASDAQ:MYOKBioMarin PharmaceuticalNASDAQ:BMRNView All CompetitorsInsiders & InstitutionsWalleye Trading LLCSold 6,100 shares on 5/17/2024Ownership: 0.000%PEAK6 Investments LLCSold 100 shares on 5/15/2024Ownership: 0.000%Benjamin HickeySold 1,597 sharesTotal: $94,254.94 ($59.02/share)Benjamin HickeySold 2,090 sharesTotal: $123,142.80 ($58.92/share)Jamie ChristensenSold 1,531 sharesTotal: $90,038.11 ($58.81/share)View All Institutional Transactions MRTX Stock Analysis - Frequently Asked Questions How were Mirati Therapeutics' earnings last quarter? Mirati Therapeutics, Inc. (NASDAQ:MRTX) issued its quarterly earnings data on Monday, November, 6th. The biotechnology company reported ($2.49) earnings per share for the quarter, beating analysts' consensus estimates of ($2.83) by $0.34. The business's quarterly revenue was up 203.7% compared to the same quarter last year. Does Mirati Therapeutics have any subsidiaries? Mirati Therapeutics subsidiaries include these companies: MethylGene, MethylGene Inc., and Mirati Therapeutics B.V.. What other stocks do shareholders of Mirati Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU) and Netflix (NFLX). This page (NASDAQ:MRTX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirati Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mirati Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
